The fanconi anaemia/BRCA pathway

Nature Reviews Cancer

Volumn 3, Issue 1, 2003, Pages 23-34

  D'Andrea, Alan D ^a   Grompe, Markus ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; MRE11 PROTEIN; NIBRIN; PROTEIN; RAD50 PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; FANCA PROTEIN, HUMAN; FANCA PROTEIN, MOUSE; FANCONI ANEMIA GROUP A PROTEIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; CELL CYCLE S PHASE; COMPLEX FORMATION; DISEASE ASSOCIATION; DNA CROSS LINKING; DNA REPAIR; FANCONI ANEMIA; HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; ANIMAL; CHROMOSOME BREAKAGE; DISEASE MODEL; GENETIC COMPLEMENTATION; GENETICS; MOUSE; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BRCA1 PROTEIN; CHROMOSOME BREAKAGE; DISEASE MODELS, ANIMAL; DNA REPAIR; DNA-BINDING PROTEINS; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP A PROTEIN; GENETIC COMPLEMENTATION TEST; HUMANS; MICE; PROTEINS; SIGNAL TRANSDUCTION;

EID: 0037268338     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc970     Document Type: Review

References (120)

1. Grompe, M. & D'Andrea, A. Fanconi anemia and DNA repair. Hum. Mol. Genet. 10, 2253-2259 (2001).
2. Joenje, H. & Patel, K. J. The emerging genetic and molecular basis of Fanconi anaemia. Nature Rev. Genet. 2, 446-457 (2001).
3. Auerbach, A. D. Fanconi anemia. Dermatol. Clin. 13, 41-49 (1995).
4. Alter, B. P. Fanconi anemia and malignancies. Am. J. Hematol. 53, 99-110 (1996).
5. Rosenberg, P. S., Greene, M. H. & Alter B. P. Cancer incidence in persons with Fanconi's anemia. Blood 5 Sept 2002 (doi:10.1182/blood-2002-05-1498).
6. D'Andrea, A. D. & Grompe, M. Molecular biology of Fanconi anemia: implications for diagnosis and therapy. Blood 90, 1725-1736 (1997).
7. Kubbies, M., Schindler, D., Hoehn, H., Schinzel, A. & Rabinovitch, P. S. Endogenous blockage and delay of the chromosome cycle despite normal recruitment and growth phase explain poor proliferation and frequent edomitosis in Fanconi anemia cells. Am. J. Hum. Genet. 37, 1022-1030 (1985).
8. Kaiser, T. N. et al. Flow cytometric characterization of the response of Fanconi's anemia cells to mitomycin C treatment. Cytometry 2, 291-297 (1982).
9. Akkan, Y. M. et al. The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. Mol. Genet. Metab. 74, 403-412 (2001).
10. Auerbach, A. D. Fanconi anemia diagnosis and the diepoxybutane (DEB) test. Exp. Hematol. 21, 731-733 (1993).
11. Waisfisz, Q. et al. Spontaneous functional correction of homozygous fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism. Nature Genet. 22, 379-383 (1999).
12. Pulsipher, M. et al. Subtyping analysis of Fanconi anemia by immunoblotting and retroviral gene transfer. Mol. Med. 4, 468-479 (1998).
13. Hanenberg, H. et al. Phenotypic correction of primary Fanconi anemia T cells with retroviral vectors as a diagnostic tool. Exp. Hematol. 30, 410-420 (2002).
14. Guinan, E. C., Lopez, K. D., Huhn, R. D., Felser, J. M. & Nathan, D. G. Evaluation of granulocyte-macrophage colony-stimulating factor for treatment of pancytopenia in children with fanconi anemia. J. Pediatr. 124, 144-150 (1994).
15. Davies, S. M. et al. Unrelated donor bone marrow transplantation for Fanconi anemia. Bone Marrow Transplant. 17, 43-47 (1996).
16. Gluckman, E. et al. Transplantation of embilical cord blood in Fanconi's anemia. Nouvelle Revue Francaise d Hematologie 32, 423-425 (1990).
17. Wagner, J. E. Umbilical cord blood stem cell transplantation. Am. J. Pedatr. Hematol. Oncol. 15, 169-174 (1993).
18. Yoshimasu, T. et al. Prompt and durable hematopoietic reconstitution by unrelated cord blood transplantation in a child with Fanconi anemia. Bone Marrow Transplant. 27, 767-769 (2001).
19. Vedinsky, Y., Rechitsky, S., Schoolcraft, W., Strom, C. & Kuliev, A. Preimplantation diagnosis for Fanconi anemia combined with HLA matching. JAMA 285, 3130-3133 (2001).
20. Liu, J. M. et al. Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC). Hum. Gene Ther. 10, 2337-2346 (1999).
21. Liu, J. M. et al. Retroviral mediated gene transfer of the Fanconi anemia complementation group C gene to hematopoietic progenitors of group C patients. Hum. Gene Ther. 8, 1715-1730 (1997).
22. Strathdee, C. A., Gavish, H., Shannon, W. R. & Buchwald, M. Cloning of cDNAs for Fanconi's anaemia by functional complementation. Nature 356, 763-767 (1992). Describes the first successful cloning of a Fanconi anemia cDNA, by functional complementation of an FA-C lymphoblast line. A similar strategy was subsequently used for the cloning of the FANCA, FANCG, FANCF and FANCE cDNAs.
23. Lo Ten Foe, J. R. et al. Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. Nature Genet. 14, 320-323 (1996).
24. de Winter, J. P. et al. Isolation of a cDNA representing the fanconi anemia complementation group E gene. Am. J. Hum. Genet. 67, 1306-1308 (2000).
25. de Winter, J. P. et al. The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nature Genet. 24, 15-16 (2000).
26. de Winter, J. R. et al. The Fanconi anaemia group G gene FANCG is identical with XRCC9. Nature Genet. 20, 281-283 (1998).
27. Positional Cloning of the Fanconi anaemia group A gene. The Fanconi anaemia/breast cancer consortium. Nature Genet. 14, 324-328 (1996).
28. Timmers, C. et al. Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol. Cell 7, 241-248 (2001). Describes the position cloning of the Fanconi anaemia gene, FANCD2. This paper also shows that the FANCD2 cDNA can functionally complement the mitomycin C sensitivity of FA-D2 cells.
29. Whitney, M. A., Jakobs, P., Kaback, M., Moses, R. E. & Grompe, M. The Ashkenazi Jewish Fanconi anemia mutation: incidence among patients and carrier frequency in the at-risk population. Hum. Mutat. 3, 339-341 (1994).
30. Vedander, P. C. et al. Carrier frequency of the IVS4 + 4 A→T mutation of the Fanconi anemia gene FAC in the Ashkenazi Jewish population. Blood 86, 4034-4038 (1995).
31. Faivre, L. et al. Association of complementation group and mutation type with clinical outcome in fanconi anemia. Blood 96, 4064-4070 (2000).
32. Gillio, A. P., Verlander, P. C., Batish, S. D., Giampietro, P. F. & Auerbach, A. D. Phenotypic consequences of mutations in the Fanconi anemia FAC gene: an International Fanconi Anemia Registry study. Blood 90, 105-110 (1997).
33. Liu, T. et al. Cloning and characterization of the zebrafish homologue of the Fanconi anemia protein, FANCD2. Blood 100, 43a (2002).
34. D'Andrea, A. D. Fanconi anaemia forges a novel pathway. Nature Genet. 14, 240-242 (1996).
35. Carreau, M. & Buchwald, M. Fanconi's anemia: what have we learned from the genes so far? Mol. Med. Today 4, 201-206 (1998).
36. Kupfer, G. M., Naf, D., Suliman, A., Pulsipher, M. & D'Andrea, A. D. The Fanconi anaemia proteins, FAA and FAC, interact to form a nuclear complex. Nature Genet. 17, 487-490 (1997).
37. Garcia-Higuera, I., Kuang, Y., Naf, D., Wasik, J. & D'Andrea, A. D. Fanconi anemia proteins FANCA, FANCC, and FANCG/XRCC9 interact in a functional nuclear complex. Mol. Cell. Biol. 19, 4866-4873 (1999).
38. Yamashita, T. et al. The Fanconi anemia pathway requires FAA phosphorylation and FAA/FAC nuclear accumulation. Proc. Natl. Acad. Sci. USA 95, 13085-13090 (1998).
39. de Winter, J. P. et al. The fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG. Hum. Mol. Genet. 9, 2665-2674 (2000). Shows that the FANCC, FANCG, FANCA and FANCF proteins accumulate as a complex in the nucleus of normal human cells, supporting the concept of an FA pathway.
40. Medhurst, A. L., Huber, P. A., Waisfisz, Q., de Winter, J. P. & Mathew, C. G. Direct interactions of the five known Fanconi anaemia proteins suggest a common functional pathway. Hum. Mol. Genet. 10, 423-429 (2001).
41. Garcia-Higuera, I., Kuang, Y., Denham, J. & D'Andrea, A. D. The fanconi anemia proteins FANCA and FANCG stabilize each other and promote the nuclear accumulation of the fanconi anemia complex. Blood 96, 3224-3230 (2000).
42. Qiao, F., Moss, A. & Kupfer, G. M. Fanconi anemia proteins localize to chromatin and the nuclear matrix in a DNA damage- and cell cycle-regulated manner. J. Biol. Chem. 276, 23391-23396 (2001).
43. Pace, P. et al. FANCE: the link between Fanconi anaemia complex assembly and activity. EMBO J. 21, 3414-3423 (2002). Shows that the FANCE gene is a component of the FA complex, is required for the accumulation of FANCC in the nucleus, and provides a functional connection between the FA complex and FANCD2.
44. Nakanishi, K. et al. Functional analysis of patient-derived mutations in the Fanconi anemia gene, FANCG/XRCC9. Exp. Hematol. 29, 842-849 (2001).
45. Garcia-Higuera, I. et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 7, 249-262 (2001). Shows that six cloned FA proteins (A, C, D2, E, F and G) interact in a common pathway, resulting in the monoubiquitylation of FANCD2 and its targeting to BRCA1-containing nuclear foci.
46. Taniguchi, T. et al. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 100, 2414-2420 (2002).
47. Wang, Y. et al. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev. 14, 927-939 (2000).
48. Lorick, K. L. et al. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc. Natl. Acad. Sci. USA 96, 11364-11369 (1999).
49. Patel, K. J. et al. Involvement of Brca2 in DNA repair. Mol. Cell 1, 347-357 (1998).
50. Kraakman-van der Zwet, M. et al. Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol. Cell. Biol. 22, 669-679 (2002).
51. McAllister, K. A. et al. Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene. Cancer Res. 62, 990-994 (2002).
52. Howlett, N. G. et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297, 606-609 (2002). Shows that some rare FA patients have biallelic inactivation of the BRCA2 gene. Cells from FA-D1 cells can be functionally complemented with the BRCA2 gene.
53. Digweed, M. et al. Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia. Carcinogenesis 23, 1121-1126 (2002).
54. Folias, A. et al. BRCA1 interacts directly with the Fanconi anemia protein, FANCA. Hum. Mol. Genet. 11, 2591-2597 (2002).
55. Margossian, S. et al. Regulated interaction of the Fanconi anemia protein, FANCD2, with damaged chromatin. Blood 100, 9a (2002).
56. D'Andrea, A. D. & Pellman, D. Deubiquitinating enzymes: A new class of biological regulators. Crit. Rev. Biochem. Mol. 33, 337-352 (1998).
57. Gatti, R. A The inherited basis of human radiosensitivity. Acta Oncol. 40, 702-711 (2001).
58. Alter, B. P. Radiosensitivity in Fanconi's anemia patients. Radiother. Oncol. 62, 345-347 (2002).
59. Khanna, K. et al. in DNA Damage and Repair (eds Nickoloff, J. A. & Hoekstra, M.) 395-442 (Humana Press, Totowa, New Jersey, 1999).
60. Banin, S. et al. Enhance phosphorylation of p53 by ATM in response to DNA damage. Science 281, 1674-1677 (1998).
61. Canman, C. E. et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281, 1677-1679 (1998).
62. Lim, D. S. et al. ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature 404, 613-617 (2000).
63. Gatei, M. et al. ATM-dependent phosphorylation of nibrin in response to radiation exposure. Nature Genet. 25, 115-119 (2000).
64. Cortez, D., Wang, Y., Qin, J. & Elledge, S. J. Requirement of ATM-dependent phosphorylation of Brca1 in the DNA damage response to double-strand breaks. Science 286, 1162-1166 (1999).
65. Taniguchi, T. et al. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell 109, 459-472 (2002). Shows that the FANCD2 protein undergoes two discrete post-translational modifications - an ATM-dependent phosphorylation and an FA-complex-dependent monoubiquitylation. Each modification activates a different cellular function.
66. Xu, B., Kim, S. & Kastan, M. B. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol. Cell. Biol. 21, 3445-3450 (2001).
67. Shiloh, Y. ATM and ATR: networking cellular responses to DNA damage. Curr. Opin. Genet. Dev. 11, 71-77 (2001).
68. Carney, J. P. Chromosomal breakage syndromes. Curr. Opin. Immunol. 11, 443-447 (1999).
69. Petrini, J. H. The Mre11 complex and ATM: collaborating to navigate S phase. Curr. Opin. Cell Biol. 12, 293-296 (2000).
70. Bressan, D. A., Baxter, B. K. & Petrini, J. H. The Mre11-Rad50-Xrs2 protein complex facilitates homologous recombination-based double-strand break repair in Saccharomyces cerevisiae. Mol. Cell. Biol. 19, 7681-7687 (1999).
71. Wu, X. et al. Independence of R/M/N focus formation and the presence of intact BRCA1. Science 289, 11 (2000).
72. Resnick, I. B. et al. Nijmegen breakage syndrome: clinical characteristics and mutation analysis in eight unrelated Russian families. J. Pediatr. 140, 355-361 (2002).
73. -/- cells have mitomycin C sensitivity, similar to the defect observed in FA cells. Moreover, NBS1 and FANCD2 interact in an S-phase checkpoint function and in repair of DNA crosslinks.
74. Shimamura, A. et al. A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood 29 Aug 2002 [epub ahead of print].
75. Chen, M. et al. Inactivation of Fac in mice produces inducible chromosomal instability and reduced fertility reminiscent of Fanconi anaemia. Nature Genet. 12, 448-451 (1996).
76. Whitney, M. A. et al. Germ cell defects and hematopoietic hypersensitivity to gamma-interferon in mice with a targeted disruption of the Fanconi anemia C gene. Blood 88, 49-58 (1996). Describes a knockout of the murine Fancc gene. Primary cells isolated from the knockout animal have chromosome instability and γ-interferon hypersensitivity.
77. Noll, M. et al. Fanconi anemia group A and C double-mutant mice. Functional evidence for a multi-protein Fanconi anemia complex. Exp. Hematol. 30, 679-688 (2002).
78. Rio, P. et al. In vitro phenotypic correction of hematopoietic progenitors from Fanconi anemia group A knockout mice. Blood 100, 2032-2039 (2002).
79. Yang, Y. et al. Targeted disruption of the murine Fanconi anemia gene, Fancg/Xrcc9. Blood 96, 3435-3440 (2001).
80. Koomen, M. et al. Reduced fertility and hypersensitivity to mitomycin C characterize Fancg/Xrcc9 null mice. Hum. Mol. Genet. 11, 273-281 (2002).
81. Haneline, L. S. et al. Loss of FancC function results in decreased hematopoietic stem cell repopulating ability. Blood 94, 1-8 (1999).
82. -/- mice. Blood 91, 4092-4098 (1998).
83. Rathbun, R. K. et al. Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells. Blood 90, 974-985 (1997).
84. Rathbun, R. K. et al. Interferon-gamma-induced apoptotic responses of fanconi anemia group C hematopoietic progenitor cells involve caspase 8-dependent activation of caspase 3 family members. Blood 96, 4204-4211 (2000).
85. Carreau, M. et al. Bone marrow failure in the Fanconi anemia group C mouse model after DNA damage. Blood 91, 2737-2744 (1998).
86. Noll, M., Bateman, R. L., D'Andrea, A. D. & Grompe, M. Preclinical protocol for in vivo selection of hematopoietic stem cells conected by gene therapy in Fanconi anemia group C. Mol. Ther. 3, 14-23 (2001).
87. Battalle, K. P. et al. In vivo selection of wild-type hematopoietic stem cells in a murine model of Fanconi anemia. Blood 94, 2151-2158 (1999).
88. Connor, F. et al. Tumorgenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nature Genet. 17, 423-430 (1997).
89. Ludwig, T., Fisher, P., Murty, V. & Efstratiadis, A. Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice. Oncogene 20, 3937-3948 (2001).
90. Ludwig, T., Chapman, D. L., Papaioannou, V. E. & Efstratiadis, A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev. 11, 1226-1241 (1997).
91. Shu, Z., Smith, S., Wang, L., Rice, M. C. & Kmiec, E. B. Disruption of muREC2/RAD51L1 in mice results in early embryonic lethality which can be partially rescued in a p53(-/-) background. Mol. Cell. Biol. 19, 8686-8693 (1999).
92. Liu, C. Y., Flesken-Nikitin, A., Li, S., Zeng, Y. & Lee, W. H. Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes Dev. 10, 1835-1843 (1996).
93. Shen, S. X. et al. A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene 17, 3115-3124 (1998).
94. Painter, R. B. Radioresistant DNA synthesis: an intrinsic feature of ataxia telangiectasia. Mutat. Res. 84, 183-190 (1981).
95. Centurion, S. A., Kuo, H. R. & Lambert, W. C. Damage-resistant DNA synthesis in fanconi anemia cells treated with a DNA cross-linking agent. Exp. Cell Res. 260, 216-221 (2000).
96. Sala-Trepat, M. et al. Arrest of S-phase progression is impaired in fanconi anemia cells. Exp. Cell Res. 260, 208-215 (2000).
97. Akkari, Y. M., Bateman, R. L., Relfsteck, C. A., Olson, S. B. & Grompe, M. DNA replication is required to elicit cellular responses to psoralen-induced DNA interstrand cross-links. Mol. Cell. Biol. 20, 8283-8289 (2000). Shows that DNA crosslinks cause a cellular arrest in S phase. The data indicate that crosslink repair is mediated by homologous recombination repair in S phase.
98. Escarceller, M., Rousset, S., Moustacchi, E. & Papadopoulo, D. The fidelity of double strand breaks processing is impaired in complementation groups B and D of Fanconi anemia, a genetic instability syndrome. Somatic Cell Mol. Genet. 23, 401-411 (1997).
99. Lundberg, R., Mavinakere, M. & Campbell, C. Defecient DNA end joining activity in extracts from fanconi anemia fibroblasts. J. Biol. Chem. 276, 9543-9549 (2001).
100. Escarceller, M. et al. Fanconi anemia C gene product plays a role in the fidelity of blunt DNA end-joining. J. Mol. Biol. 279, 375-385 (1998).
101. Scully, R., Puget, N. & Vlasakova, K. DNA polymerase stalling, sister chromatid recombination and the BRCA genes. Oncogene 19, 6176-6183 (2000).
102. Moynahan, M. E., Pierce, A. J. & Jasin, M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol. Cell. 7, 263-272 (2001).
103. -/- cells have an underlying defect in homologous recombination repair and in sister-chromatid exchange.
104. Larminat, F., Germanier M., Papouli, E. & Defais, M. Deficiency in BRCA2 leads to increase in non-conservative homologous recombination. Oncogene 21, 5188-5192 (2002).
105. Wong, A. K., Pero, R., Ormonde, P. A., Tavtigian, S. V. & Bartel, P. L. RAD51 interacts with the evolutionary conserved BRC motifs in the human breast cancer susceptibility gene Brca2. J. Biol. Chem. 272, 31941-31944 (1997).
106. Wilson, J. H. & Elledge, S. J. Cancer: BRCA2 enters the fray. Science 297, 1822-1823 (2002).
107. Yang, H. et al. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure Science 297, 1837-1848 (2002). Describes the first crystal structure for a domain of a Fanconi anaemia protein, BRCA2/FANCD2. This paper also shows that the carboxyl terminus of the protein has a regulated interaction with DNA.
108. Scully, R. et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90, 425-435 (1997).
109. Zickler, D. & Kleckner, N. Meiotic chromosomes: integrating structure and function. Annu. Rev. Genet. 33, 603-754 (1999).
110. Moynahan, M. E., Chiu, J. W., Koller, B. H. & Jasin, M. Brca1 controls homology-directed DNA repair. Mol. Cell 4, 511-518 (1999).
111. Moynahan, M. E., Cui, T. Y. & Jasin, M. Homology-directed DNA repair, mitomycin-C resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 61, 4842-4850 (2001).
112. Meyn, S., D'Andrea, A., Grompe, M. & Wang, W. The involvement of Fanconi Anemia proteins in homologous genetic recombination. Am. J. Hum. Genet. 69, 750 (2001).
113. Thyagarajan, B. & Campbell, C. Elevated homologous recombination activity in fanconi anemia fibroblasts. J. Biol. Chem. 272, 23328-23333 (1997).
114. Papadopoulo, D., Guillouf, C., Mohrenweiser, H. & Moustacchi, E. Hypomutability in Fanconi anemia cells is associated with increased deletion frequency at the HPRT locus. Proc. Natl Acad. Sci. USA 87, 8383-8387 (1990).
115. Sala-Trepat, M., Boyse, J., Richard, P., Papadopoulo, D. & Moustacchi, E. Frequencies of HPRT lymphocytes and glycophorin A variants erythrocytes in Fanconi anemia patients, their parents and control donors. Mut. Res. 289, 115-126 (1993).
116. Laquerbe, A., Sala-Trepat, M., Vives, C., Escarceller, M. & Papadopoulo, D. Molecular spectra of HPRT deletion mutations in circulating T-lymphocytes in Fanconi anemia patients. Mutat. Res. 431, 341-350 (1999).
117. McHugh, P. J., Spanswick, V. J. & Hartley, J. A. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol. 2, 483-490 (2001).
118. Wang, X. et al. Involvement of nucleotide excision repair in a recombination-independent and error-prone pathway of DNA interstrand cross-link repair. Mol. Cell. Biol. 21, 713-720 (2001).
119. Bessho, T., Mu, D. & Sancar, A. Initiation of DNA interstrand cross-link repair in humans: the nucleotide excision repair system makes dual incisions 5′ to the cross-linked base and removes a 22- to 28-nucleotide-long damage-free strand. Mol. Cell. Biol. 17, 6822-6830 (1997).
120. De Silva, I. U., McHugh, P. J., Clingen, P. H. & Hartley, J. A. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol. Cell. Biol. 20, 7980-7990 (2000).